Highlight
– The KUNPENG trial reported an objective response rate (ORR) of 48.8% for vebreltinib in patients with high-level MET-amplified non-small-cell lung cancer (NSCLC).
– Antitumor activity was observed in both chemotherapy-naive and previously treated patient populations.
– The safety profile was manageable, with treatment-related adverse events predominantly involving liver function abnormalities.
– Vebreltinib represents a potent Type Ib MET inhibitor specifically targeting the gene copy number threshold of six or higher.